Frovocimab
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9[1].
Product Specifications
CAS Number
1643672-70-1
Product Name Alternative
LY 3015014
UNSPSC
12352203
Target
PCSK9
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/frovocimab.html
Purity
99.87
Solubility
10 mM in DMSO
Smiles
[Frovocimab]
Molecular Weight
(146.38 kDa)
References & Citations
[1]Krista M Schroeder, et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res. 2015 Nov;56 (11) :2124-32.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![iFluor™ 647 Conjugated MUC1 Mouse Monoclonal Antibody [PSH0-48]](https://cdn.genprice.uk/products/992/68dd1c8b061270361ea81715/imageurl/ha600107f.webp)
HA600107F 100 µL
iFluor™ 647 Conjugated MUC1 Mouse Monoclonal Antibody [PSH0-48]
Sign In for Pricing
View Details 
AP52629PU-N 400 µL
MCAF2 (ATF7IP2) (Center) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
